GO:0009298 GDP-mannose biosynthetic process: Nucleotide-Sugar Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009298 (GDP-mannose biosynthetic process) describes the chemical reactions and pathways that form GDP-mannose, the activated nucleotide-sugar donor used for mannosylation and fucosylation reactions.
• GDP-mannose is synthesized from mannose-1-phosphate and GTP by GDP-mannose pyrophosphorylase (GMPPB in humans, GMPP in bacteria), and is interconverted with GDP-fucose by GDP-mannose 4,6-dehydratase and GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase.
• Loss of GDP-mannose biosynthesis causes congenital disorders of glycosylation (GMPPB-CDG) with lysosomal dysfunction and acid alpha-glucosidase deficiency.
• In triple-negative breast cancer, GDP-mannose suppresses homologous recombination repair and potentiates antitumor immunity, linking this pathway to DNA repair and immunotherapy.
• GDP-mannose pyrophosphorylase is an efficient antibacterial target in Xanthomonas citri for citrus canker control, showing the pathway's agricultural relevance.
• Mannose supplementation can correct GDP-mannose deficiency in cultured fibroblasts from some CDG patients, providing a potential therapeutic strategy.
Description
GDP-mannose biosynthetic process (GO:0009298) is the set of biochemical reactions that produce guanosine diphosphate mannose (GDP-mannose), a nucleotide-sugar composed of mannose in glycosidic linkage with guanosine diphosphate. This process is essential because GDP-mannose serves as the activated donor substrate for mannosyltransferases and, after further conversion, for fucosyltransferases, thereby supplying mannose and fucose residues to glycoproteins, glycolipids, and polysaccharides. The pathway is conserved from bacteria to humans and is required for protein glycosylation, cell wall biosynthesis in microorganisms, and plant cell wall polysaccharide formation. Researchers study GO:0009298 because defects in GDP-mannose biosynthesis cause congenital disorders of glycosylation (CDG) and because the pathway is a potential target in cancer and infectious disease. In recent years, GDP-mannose has emerged as a metabolite with signaling roles beyond glycosylation, including suppression of homologous recombination repair in triple-negative breast cancer. Understanding the enzymes, regulation, and disease connections of GDP-mannose biosynthesis is therefore important for glycobiology, cancer biology, and antimicrobial drug development.
GDP-mannose biosynthetic process At A Glance
| GO ID | GO:0009298 |
|---|---|
| GO term | GDP-mannose biosynthetic process |
| Ontology | biological_process |
| Synonym | GDP-mannose anabolism, GDP-mannose biosynthesis, GDP-mannose formation, GDP-mannose synthesis |
| Major function | Synthesis of GDP-mannose, the activated donor for mannosylation and fucosylation reactions |
| Key enzymes | GDP-mannose pyrophosphorylase (GMPPB), GDP-mannose 4,6-dehydratase (GMDS), GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase (TSTA3) |
| Substrates | Mannose-1-phosphate, GTP |
| Products | GDP-mannose, diphosphate |
| Related pathways | Fucosylation, protein glycosylation, cell wall biosynthesis, ascorbate biosynthesis in plants |
What Is GO:0009298?
GO:0009298 (GDP-mannose biosynthetic process) is defined by QuickGO as the chemical reactions and pathways resulting in the formation of GDP-mannose, a substance composed of mannose in glycosidic linkage with guanosine diphosphate. In practice, this includes the enzymatic conversion of mannose-1-phosphate and GTP to GDP-mannose by GDP-mannose pyrophosphorylase, as well as the interconversion reactions that generate GDP-mannose from other nucleotide-sugars such as GDP-fucose precursors.
Why Is GDP-mannose biosynthetic process Important in Cell Biology?
GDP-mannose biosynthetic process is important because GDP-mannose is the central activated mannose donor for glycosylation reactions that modify proteins and lipids, and it is also the precursor for GDP-fucose, which is required for fucosylation. Defects in this pathway cause congenital disorders of glycosylation, such as GMPPB-CDG, which manifests with lysosomal dysfunction and acid alpha-glucosidase deficiency. In cancer, GDP-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer, making the pathway a potential therapeutic target. In bacteria, GDP-mannose pyrophosphorylase is an efficient target for controlling citrus canker caused by Xanthomonas citri. In plants, GDP-mannose is involved in ascorbate biosynthesis and cell wall polysaccharide formation. Thus, GO:0009298 is relevant to human disease, cancer therapy, antimicrobial development, and plant biology.
• Provides GDP-mannose, the activated donor for mannosylation of proteins and lipids.
• Supplies GDP-fucose after conversion by GDP-mannose 4,6-dehydratase and epimerase/reductase, enabling fucosylation.
• Defects cause GMPPB-CDG with lysosomal dysfunction and acid alpha-glucosidase deficiency.
• GDP-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
• GDP-mannose pyrophosphorylase is a target in Xanthomonas citri for citrus canker control.
• Mannose supplementation can correct GDP-mannose deficiency in some CDG fibroblasts.
• Involved in plant ascorbate biosynthesis and cell wall polysaccharide formation.
• GDP-mannose 3,5-epimerase can produce GDP-altrose, expanding the reaction repertoire.
• Fluorinated rhamnosides can inhibit cellular fucosylation, linking GDP-mannose metabolism to glycoengineering.
• Relevant to microbial L-fucose production through engineered GDP-mannose mannosyl hydrolase.
What Happens During GDP-mannose biosynthetic process?
Formation of mannose-1-phosphate
In simple terms: The cell first converts mannose into an activated form called mannose-1-phosphate.
GDP-mannose biosynthesis begins with mannose-6-phosphate, which is isomerized to mannose-1-phosphate by phosphomannomutase. This step is required to activate mannose for nucleotide-sugar formation. In cultured fibroblasts from some CDG patients, mannose supplementation can bypass upstream defects and restore GDP-mannose levels, indicating that mannose-1-phosphate availability is a key control point.
Condensation of mannose-1-phosphate with GTP
In simple terms: An enzyme called GDP-mannose pyrophosphorylase joins mannose-1-phosphate to GTP to make GDP-mannose.
The central reaction of GO:0009298 is catalyzed by GDP-mannose pyrophosphorylase (GMPPB in humans, GMPP in bacteria), which condenses mannose-1-phosphate with GTP to form GDP-mannose and diphosphate. This enzyme is conserved across species and is essential for providing GDP-mannose for glycosylation. In Xanthomonas citri, GDP-mannose pyrophosphorylase is an efficient target for citrus canker control, demonstrating the importance of this step in bacteria.
Interconversion with GDP-fucose precursors
In simple terms: GDP-mannose can be converted into GDP-fucose, another sugar donor used for fucosylation.
GDP-mannose is converted to GDP-4-keto-6-deoxymannose by GDP-mannose 4,6-dehydratase (GMDS), which is then converted to GDP-fucose by GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase (TSTA3). This pathway links GDP-mannose biosynthesis to fucosylation of glycoproteins and glycolipids. GDP-mannose 3,5-epimerase can also produce GDP-altrose, expanding the range of nucleotide-sugars derived from GDP-mannose.
Regulation by substrate availability and disease states
In simple terms: The pathway is turned up or down depending on how much mannose is available and whether enzymes are working properly.
GDP-mannose levels are regulated by the availability of mannose-1-phosphate and GTP, and by the activity of GDP-mannose pyrophosphorylase. In GMPPB-CDG, mutations in GMPPB reduce GDP-mannose biosynthesis, leading to lysosomal dysfunction and acid alpha-glucosidase deficiency. In triple-negative breast cancer, GDP-mannose suppresses homologous recombination repair, indicating that the pathway can influence DNA repair and antitumor immunity.
Role in glycosylation and cell wall biosynthesis
In simple terms: GDP-mannose is used as a building block to add mannose to proteins and to build cell walls in bacteria and plants.
GDP-mannose serves as the donor substrate for mannosyltransferases in the endoplasmic reticulum and Golgi apparatus, where it contributes to N-linked and O-linked glycosylation. In bacteria, GDP-mannose is used for cell wall polysaccharide biosynthesis, and in plants it contributes to cell wall polysaccharides and ascorbate biosynthesis. This broad utilization explains why GO:0009298 is essential for diverse organisms.
Key Genes Involved in GO:0009298 GDP-mannose biosynthetic process
The following genes and proteins are directly involved in GDP-mannose biosynthetic process (GO:0009298) and its downstream utilization.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GMPPB | GDP-mannose pyrophosphorylase; converts mannose-1-phosphate and GTP to GDP-mannose | Mutations cause GMPPB-CDG with lysosomal dysfunction |
| GMPPA | Regulatory subunit of GDP-mannose pyrophosphorylase | Modulates GMPPB activity and GDP-mannose levels |
| PMM2 | Phosphomannomutase 2; converts mannose-6-phosphate to mannose-1-phosphate | Defects cause CDG-Ia and reduce GDP-mannose |
| GMDS | GDP-mannose 4,6-dehydratase; converts GDP-mannose to GDP-4-keto-6-deoxymannose | Links GDP-mannose to fucosylation |
| TSTA3 | GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase; produces GDP-fucose | Required for fucosylation of glycoproteins |
| GMD | GDP-mannose 4,6-dehydratase in bacteria and plants | Bacterial fucosylation and cell wall biosynthesis |
| GMPP | GDP-mannose pyrophosphorylase in bacteria | Target for citrus canker control in Xanthomonas citri |
| MPG1 | GDP-mannose pyrophosphorylase in plants | Ascorbate biosynthesis and cell wall formation |
| VTC1 | GDP-mannose pyrophosphorylase in Arabidopsis | Ascorbate biosynthesis |
| GMPPB-CDG | Congenital disorder of glycosylation caused by GMPPB mutations | Lysosomal dysfunction and acid alpha-glucosidase deficiency |
| FUT8 | Fucosyltransferase 8; uses GDP-fucose derived from GDP-mannose | Fucosylation of glycoproteins |
| SLC35C1 | GDP-fucose transporter | Transports GDP-fucose into Golgi for fucosylation |
| GFUS | GDP-fucose synthase | Alternative name for TSTA3 |
| FKP | Fucokinase/GDP-fucose pyrophosphorylase | Salvage pathway for GDP-fucose |
| MAN1B1 | Mannosidase involved in N-glycan processing | Indirectly linked to GDP-mannose utilization |
| ALG1 | Mannosyltransferase using GDP-mannose | N-linked glycosylation |
| DPM1 | Dolichol-phosphate mannosyltransferase using GDP-mannose | Glycosylphosphatidylinositol anchor biosynthesis |
| PIGM | GPI mannosyltransferase using GDP-mannose | GPI anchor biosynthesis |
How Is GDP-mannose biosynthetic process Regulated?
GDP-mannose biosynthetic process is regulated primarily by substrate availability and enzyme expression. Mannose supplementation can correct GDP-mannose deficiency in cultured fibroblasts from some CDG patients, indicating that the pathway responds to mannose supply. GDP-mannose pyrophosphorylase activity is essential for maintaining GDP-mannose levels, and mutations in GMPPB reduce flux through the pathway. In cancer, GDP-mannose levels can influence homologous recombination repair, suggesting that the pathway may be regulated by DNA damage responses. Additionally, GDP-mannose 4,6-dehydratase and downstream enzymes control the balance between GDP-mannose and GDP-fucose, which affects fucosylation.
GDP-mannose biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GMPPB | GMPPB-CDG with lysosomal dysfunction and acid alpha-glucosidase deficiency | Patient fibroblasts, GMPPB knockout cell lines, mannose supplementation |
| PMM2 | CDG-Ia with reduced GDP-mannose | PMM2 mutant fibroblasts, mannose rescue experiments |
| GMDS | Fucosylation defects and cancer | GMDS knockout cells, fucosylation assays |
| TSTA3 | Leukocyte adhesion deficiency type II (LAD II) | TSTA3 mutant cells, fucosylation rescue |
| GMPP (Xanthomonas citri) | Citrus canker | Xanthomonas citri GMPP knockout, plant infection models |
GMPPB-CDG and lysosomal dysfunction
Mutations in GMPPB, which encodes GDP-mannose pyrophosphorylase, cause a congenital disorder of glycosylation (GMPPB-CDG) characterized by lysosomal dysfunction and acid alpha-glucosidase deficiency. This highlights the critical role of GDP-mannose biosynthesis in lysosomal enzyme glycosylation and function.
Triple-negative breast cancer and DNA repair
In triple-negative breast cancer, GDP-mannose suppresses homologous recombination repair and potentiates antitumor immunity. This suggests that modulating GDP-mannose biosynthesis could be a therapeutic strategy to enhance immunotherapy responses.
Infectious disease and antimicrobial targets
GDP-mannose pyrophosphorylase is an efficient target in Xanthomonas citri for citrus canker control, demonstrating that inhibiting GDP-mannose biosynthesis can combat bacterial pathogens. This pathway is also relevant to other microbial infections where GDP-mannose is required for cell wall biosynthesis.
Congenital disorders of glycosylation and mannose therapy
Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with congenital disorders of glycosylation, providing a potential therapeutic approach for select CDG subtypes. This underscores the importance of GDP-mannose biosynthesis in glycosylation-related diseases.
From GDP-mannose biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GMPPB loss reduce GDP-mannose levels? | GMPPB knockout cell lines (HEK293, HeLa) |
| Can mannose supplementation rescue GDP-mannose deficiency? | Patient fibroblasts with CDG mutations |
| Does GDP-mannose regulate homologous recombination repair? | Triple-negative breast cancer cell lines with GDP-mannose modulation |
| Does GMPP inhibition control Xanthomonas citri? | Xanthomonas citri GMPP knockout or inhibitor treatment |
| Does GMDS knockout alter fucosylation? | GMDS knockout cells with fucosylation assays |
| Does TSTA3 mutation affect GDP-fucose production? | TSTA3 mutant cells with GDP-fucose measurement |
How to Study the GDP-mannose biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | GDP-mannose and nucleotide-sugar levels | Quantify pathway flux in cells and tissues |
| Lectin blotting | Mannosylation and fucosylation of proteins | Assess glycosylation changes |
| Enzymatic assay | GDP-mannose pyrophosphorylase activity | Characterize mutant enzymes and inhibitors |
| CRISPR knockout screens | Genes required for GDP-mannose biosynthesis | Identify therapeutic targets |
| Glycan mass spectrometry | Structure of N- and O-glycans | Link GDP-mannose to glycosylation |
| Fucosylation assay | GDP-fucose-dependent fucosylation | Measure downstream pathway activity |
| Mannose supplementation | Rescue of GDP-mannose deficiency | Test therapeutic strategy in CDG |
| Homologous recombination assay | DNA repair efficiency | Study GDP-mannose role in cancer |
Metabolite profiling by mass spectrometry
GDP-mannose and related nucleotide-sugars can be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify pathway flux and detect deficiencies in CDG fibroblasts. This method is essential for confirming that genetic perturbations affect GDP-mannose biosynthesis.
Glycosylation analysis by lectin blotting and mass spectrometry
Changes in mannosylation and fucosylation resulting from altered GDP-mannose biosynthesis can be assessed by lectin blotting, glycan mass spectrometry, and fucosylation assays. These methods link GO:0009298 to downstream glycosylation phenotypes.
Enzymatic assays for GDP-mannose pyrophosphorylase
GDP-mannose pyrophosphorylase activity can be measured in cell lysates using mannose-1-phosphate and GTP, with detection of GDP-mannose formation. Such assays are used to characterize mutant enzymes and test inhibitors.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for GDP-mannose biosynthesis and its downstream functions, such as glycosylation and DNA repair. These screens can reveal synthetic lethal interactions and therapeutic targets.
How CRISPR Can Be Used to Study GO:0009298 GDP-mannose biosynthetic process
Knockout
CRISPR knockout of GMPPB, PMM2, GMDS, or TSTA3 can abolish GDP-mannose biosynthesis, leading to glycosylation defects and, in the case of GMPPB, lysosomal dysfunction. These models are used to study the consequences of GDP-mannose deficiency and to test rescue strategies such as mannose supplementation.
Point Mutation
CRISPR point mutation can introduce patient-specific missense mutations in GMPPB or PMM2 to model congenital disorders of glycosylation and assess residual enzyme activity. Such models help determine genotype-phenotype relationships in GDP-mannose biosynthesis.
Knock-in
Knock-in of epitope-tagged GMPPB or GMDS allows visualization and quantification of these enzymes in living cells, facilitating studies of their localization and dynamics. Tagged knock-in models can also be used to monitor GDP-mannose biosynthesis in real time.
Overexpression
Overexpression of GMPPB or GMDS can increase GDP-mannose and GDP-fucose levels, enhancing mannosylation and fucosylation. These models are useful for producing glycoproteins with defined glycan structures and for studying the role of GDP-mannose in cancer.
How EDITGENE Supports GDP-mannose biosynthetic process Research
Researchers studying GDP-mannose biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, glycosylation, or disease. EDITGENE provides CRISPR-based cell model services to enable these functional studies.
Contact EDITGENE today to design your custom CRISPR model for GDP-mannose biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| HK1 Knockout HEK293 Cell Line | EDJ-KQ1506 | Human | 3098 | Details Get a Quote |
| MPI Knockout HEK293 Cell Line | EDJ-KQ5234 | Human | 4351 | Details Get a Quote |
| PMM1 Knockout HEK293 Cell Line | EDJ-KQ5493 | Human | 5372 | Details Get a Quote |
| PMM2 Knockout HEK293 Cell Line | EDJ-KQ5494 | Human | 5373 | Details Get a Quote |
| GMPPA Knockout HEK293 Cell Line | EDJ-KQ9085 | Human | 29926 | Details Get a Quote |
| HK1 Knockout A-549 Cell Line | EDJ-KQ21124 | Human | 3098 | Details Get a Quote |
| HK1 Knockout HCT 116 Cell Line | EDJ-KQ21125 | Human | 3098 | Details Get a Quote |
| HK1 Knockout HeLa Cell Line | EDJ-KQ21126 | Human | 3098 | Details Get a Quote |
| PMM2 Knockout HCT 116 Cell Line | EDJ-KQ27478 | Human | 5373 | Details Get a Quote |
| MPI Knockout A-549 Cell Line | EDJ-KQ28259 | Human | 4351 | Details Get a Quote |
| MPI Knockout HCT 116 Cell Line | EDJ-KQ28260 | Human | 4351 | Details Get a Quote |
| MPI Knockout HeLa Cell Line | EDJ-KQ28261 | Human | 4351 | Details Get a Quote |
| PMM1 Knockout A-549 Cell Line | EDJ-KQ28722 | Human | 5372 | Details Get a Quote |
| PMM1 Knockout HCT 116 Cell Line | EDJ-KQ28723 | Human | 5372 | Details Get a Quote |
| PMM1 Knockout HeLa Cell Line | EDJ-KQ28724 | Human | 5372 | Details Get a Quote |
Displaying Records 1 To 15 Of 20 Records
Frequently Asked Questions About GDP-mannose biosynthetic process
What is GDP-mannose biosynthetic process?
GDP-mannose biosynthetic process (GO:0009298) is the set of biochemical reactions that produce GDP-mannose, an activated nucleotide-sugar used for mannosylation and fucosylation.
What genes are involved in GDP-mannose biosynthetic process?
Key genes include GMPPB, GMPPA, PMM2, GMDS, and TSTA3, which encode enzymes that synthesize and interconvert GDP-mannose.
What is the function of GDP-mannose?
GDP-mannose serves as the donor substrate for mannosyltransferases and is converted to GDP-fucose for fucosylation of proteins and lipids.
How is GDP-mannose synthesized?
GDP-mannose is synthesized from mannose-1-phosphate and GTP by GDP-mannose pyrophosphorylase (GMPPB in humans).
What diseases are associated with GDP-mannose biosynthesis defects?
Defects cause GMPPB-CDG with lysosomal dysfunction and acid alpha-glucosidase deficiency, and are linked to cancer and infectious disease.
Can mannose supplementation correct GDP-mannose deficiency?
Yes, mannose supplementation can correct GDP-mannose deficiency in cultured fibroblasts from some patients with congenital disorders of glycosylation.
What is the role of GDP-mannose in cancer?
In triple-negative breast cancer, GDP-mannose suppresses homologous recombination repair and potentiates antitumor immunity.
How can I study GDP-mannose biosynthetic process?
You can use LC-MS/MS to measure GDP-mannose, lectin blotting for glycosylation, and CRISPR knockout models to test gene function.
What is GMPPB-CDG?
GMPPB-CDG is a congenital disorder of glycosylation caused by mutations in GMPPB, leading to lysosomal dysfunction and acid alpha-glucosidase deficiency.
Is GDP-mannose pyrophosphorylase a drug target?
Yes, GDP-mannose pyrophosphorylase is an efficient target in Xanthomonas citri for citrus canker control, and may be relevant for other pathogens.
Conclusion
GDP-mannose biosynthetic process (GO:0009298) is a fundamental metabolic pathway that supplies GDP-mannose for glycosylation and fucosylation, with critical roles in human health, cancer, and microbial pathogenesis. Understanding its enzymes, regulation, and disease connections provides opportunities for therapeutic intervention and biotechnology applications. EDITGENE offers comprehensive CRISPR cell model services to accelerate research on this pathway.
References
- 1. Ding JH et al.. 2024. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.. Sci Transl Med 16(728):eadg7740 PMID: 38170790
- 2. Smirnoff N. 2001. L-ascorbic acid biosynthesis.. Vitam Horm 61:241-66 PMID: 11153268
- 3. Fu C et al.. 2023. Rational design of GDP‑D‑mannose mannosyl hydrolase for microbial L‑fucose production.. Microb Cell Fact 22(1):56 PMID: 36964553
- 4. Gevaert O et al.. 2020. GDP-altrose as novel product of GDP-mannose 3,5-epimerase: Revisiting its reaction mechanism.. Int J Biol Macromol 165(Pt B):1862-1868 PMID: 33075338
- 5. Damiano C et al.. 2026. GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.. J Inherit Metab Dis 49(1):e70136 PMID: 41554119
- 6. Pijnenborg JFA et al.. 2021. Fluorinated rhamnosides inhibit cellular fucosylation.. Nat Commun 12(1):7024 PMID: 34857733
- 7. Alexandrino AV et al.. 2024. GDP-mannose pyrophosphorylase is an efficient target in Xanthomonas citri for citrus canker control.. Microbiol Spectr 12(6):e0367323 PMID: 38722158
- 8. Rush JS et al.. 2000. Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with Congenital Disorders of Glycosylation (CDG).. Glycobiology 10(8):829-35 PMID: 10929009
